Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

KERYX BIOPHARMACEUTICALS INC

Form 8-K March 07, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 7, 2005

Keryx Biopharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.) of Incorporation)

000-30929

13-4087132

750 Lexington Avenue New York, New York 10022 (Address of Principal Executive Offices)

(212) 531-5965

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [] Written communications pursuant to Rule 425 under the Securities Act.
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- [] Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Item 2.02. Results of Operations and Financial Condition

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

On March 7, 2005, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a press release announcing results of operations for the fourth quarter and year ended December 31, 2004. Keryx also announced that it would host a conference call on March 8, 2005, for investors where Keryx will discuss its results of operations and financial results. A copy of such press release is being furnished as Exhibit 99.1 to this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals, Inc.
(Registrant)

Date: March 7, 2005

By: /s/ Ron Bentsur

Ron Bentsur

Vice President Finance and

Investor Relations

INDEX TO EXHIBITS

Exhibit	
Number	Description
99.1	Press Release dated March 7, 2005.